Stuart has got the PoWeR! Skeletal muscle adaptations to a novel heavy progressive weighted wheel running exercise model in C57BL/6 mice
Experimental Physiology · 2024
DOI: 10.1113/ep091494 ↗At a glance
Journal article in Experimental Physiology, 2024. Written by Pieter J Koopmans and 2 co-authors. Institution: Integrative Muscle Physiology Laboratory, Appalachian State University, Boone, North Carolina, USA. Major MEDLINE topics: Resistance Training, Physical Conditioning, Animal. Cited 7 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Appalachian State University (ASU), Appalachian State University Office of Student Research, Appalachian State University Graduate Student Government Association, Department of Public Health and Exercise Science.
Abstract (original language)
Murine exercise models are developed to study the molecular and cellular mechanisms regulating muscle mass. A progressive weighted wheel running model, named ‘PoWeR’, was previously developed to serve as a more translatable alternative to involuntary resistance‐type exercise models in rodents, such as synergist ablation. However, mice still run great distances despite the added resistance as evidenced by a large glycolytic‐to‐oxidative shift in muscle fibre type. Thus, PoWeR reflects a blended resistance/endurance model. In an attempt to bias PoWeR further towards resistance‐type exercise, we developed a novel heavy PoWeR model (hPoWeR) utilizing higher wheel loads (max of 12.5 g vs 6 g). Adult male C57BL/6 mice voluntarily performed an 8‐week progressive loading protocol (PoWeR or hPoWeR). Running distance peaked at ∼5–6 km day −1 in both treatments and was maintained by PoWeR mice, but declined in the hPoWeR mice as load increased beyond 7.5 g. Peak isometric force of the gastrocnemius–soleus–plantaris complex tended to increase in wheel running treatments. Soleus mass increased by 19% and 24% in PoWeR and hPoWeR treatments, respectively, and plantaris fibre cross‐sectional area was greater in hPoWeR, compared to PoWeR. There were fewer glycolytic and more oxidative fibres in the soleus and plantaris muscles in the PoWeR treatment, but not hPoWeR. Collectively, these data suggest hPoWeR may modestly alter skeletal muscle supporting the aim of better reflecting typical resistance training adaptations, in line with decreased running volume and exposure to higher resistance. Regardless, PoWeR remains an effective hypertrophic concurrent training model in mice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Integrative Muscle Physiology Laboratory, Appalachian State University, Boone, North Carolina, USA.
- Department of Public Health and Exercise Science, Appalachian State University, Boone, North Carolina, USA.
- Cell and Molecular Biology Program, University of Arkansas, Fayetteville, Arkansas, USA.
- Department of Biology, Appalachian State University, Boone, North Carolina, USA.
ORCID profiles: Kevin A Zwetsloot
Funding
- Appalachian State University (ASU)
- Appalachian State University Office of Student Research, Appalachian State University Graduate Student Government Association
- Department of Public Health and Exercise Science
Cite
APA
Koopmans, P. J., Williams-Frey, T. D., & Zwetsloot, K. A. (2024). Stuart has got the PoWeR! Skeletal muscle adaptations to a novel heavy progressive weighted wheel running exercise model in C57BL/6 mice. Experimental Physiology. https://doi.org/10.1113/ep091494
Vancouver
Koopmans PJ, Williams-Frey TD, Zwetsloot KA. Stuart has got the PoWeR! Skeletal muscle adaptations to a novel heavy progressive weighted wheel running exercise model in C57BL/6 mice. Experimental Physiology. 2024. doi:10.1113/ep091494
BibTeX
@article{Koopmans2024,
author = {Koopmans, Pieter J and Williams-Frey, Therin D and Zwetsloot, Kevin A},
title = {Stuart has got the PoWeR! Skeletal muscle adaptations to a novel heavy progressive weighted wheel running exercise model in C57BL/6 mice},
journal = {Experimental Physiology},
year = {2024},
doi = {10.1113/ep091494}
}
EUVIMED